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Mesd is a specialized chaperone for Wnt co-receptor low-density lipoprotein receptor-related pro-
tein-5 (LRP5) and LRP6, which contain four b-propeller/epidermal growth factor modules, named
E1 to E4 from N- to C-terminal, in their extracellular domains. Herein, we demonstrated that recom-
binant Mesd protein is a general Wnt inhibitor that blocks Wnt/b-catenin signaling induced not only
by LRP6 E1-E2-binding Wnts but also by LRP6 E3-E4-binding Wnts. We also found that Mesd sup-
pressed Wnt/b-catenin signaling induced by Wnt1 in prostate cancer PC-3 cells, and inhibited tumor
growth in PC-3 xenograft model. Our results indicate that Mesd is a universal inhibitor of Wnt/LRP
signaling on the cell surface.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction able to inhibit Wnt3a-induced Wnt/b-catenin signaling in LRP5/6The low-density lipoprotein receptor-related protein-5 (LRP5)
and LRP6 are essential co-receptors for theWnt/b-catenin signaling
pathway [1]. In the absence of Wnt ligands, b-catenin is phosphor-
ylated by a multi-protein complex that marks it for ubiquitination
and degradation by the proteasome. The action of this complex is
inhibited upon binding of Wnt to its cell-surface receptors Frizzled
(Fz) and LRP. The LRP–Wnt–Fz binding results in stabilization of
cytosolic b-catenin, which enters the nucleus to activateWnt target
genes by binding to transcription factors of the T-cell factor/lym-
phoid enhancing factor family [1].
Mesd is a specializedmolecular chaperone for theWnt co-recep-
tors LRP5 and LRP6 [2–7]. Both LRP5 and LRP6 contain four b-pro-
peller/epidermal growth factor (EGF) modules, named E1 to E4
from N- to C-terminal. Mesd is speciﬁcally required for the matura-
tion of these b-propeller/EGF modules through the secretory path-
way [4]. In our previous studies, we found that recombinant Mesd
protein binds to mature LRP5 and LRP6 on the cell surface, and ischemical Societies. Published by E
, Frizzled; LRP5, low-densityexpressing cells [8]. All the identiﬁed LRP5/6 extracellular ligands
including Mesd and Wnt proteins bind to the b-propeller/EGF
repeat modules [1,4,9–12]. There are about 19 vertebrate members
of the Wnt family. Recent studies indicated different Wnt proteins
bind to distinct regions of LRP6. For example, Wnt 1, Wnt9a and
Wnt10b bind exclusively within the LRP6 E1-E2 region in vitro,
whereas Wnt3 and Wnt3a bind only to a fragment containing E3-
E4 [10–12]. We have recently demonstrated that Mesd is able to
block Wnt3a-induced Wnt/b-catenin signaling in LRP5- and LRP6-
expressing cells, and inhibits Wnt/b-catenin signaling in prostate
cancer PC-3 cells in vitro [8]. In this report, we demonstrated that
Mesd is a general inhibitor of different Wnt proteins in Wnt/LRP
signaling and suppresses PC-3 tumor growth in vivo.
2. Materials and methods
2.1. Materials
Plasmid pcDNA3.1C-Myc-hLRP5 containing the full-length
human LRP5 cDNA and plasmid pCS-Myc-hLRP6 containing the
full-length human LRP6 cDNA were from Dr. Cindy Bartels (Case
Western Reserve University, Cleveland) and Dr. Christof Niehrs
(Deutsches Krebsforschungszentrum, Heidelberg, Germany),lsevier B.V. All rights reserved.
Fig. 1. Mesd blocksWnt/b-catenin signaling induced byWnt1,Wnt3 andWnt10b in
HEK293 cells. (A) HEK293 cells in 24-well plates were transiently transfected with
0.1 lg of Wnt1, Wnt3, Wnt10b plasmid or the corresponding control vector, along
with 0.05 lg of Super8XTOPFlash construct and 0.05 lg of b-galactosidase-express-
ing vector in each well. After being incubated for 24 h, cells were treated with 1 lM
Mesd. The luciferase activity was thenmeasured 24 h later with normalization to the
activity of the b-galactosidase. Values are averages of three determinations with the
standard deviations indicated by error bars. ⁄⁄P < 0.01 compared to the control cells
without Mesd treatment. (B) HEK293 cells in 6-well plates were transiently
transfected with 1 lg of Wnt1, Wnt3, Wnt10b plasmid or the corresponding control
vector. After being incubated for 24 h, cells were treated with 1 lM Mesd. Twenty-
four hours later, the levels of total b-catenin, free b-catenin,Wnt1,Wnt3, andWnt10b
were analyzed with Western blotting using a speciﬁc antibody against each protein.
Samples were also probed with the anti-actin antibody to verify equal loading.
C. Lin et al. / FEBS Letters 585 (2011) 3120–3125 3121respectively. Plasmid pGST-E-cadherin was provided by Dr. Gail
Johnson (University of Rochester, New York). Plasmid pUSEamp-
Wnt1-HA containing the full-length mouse Wnt1 cDNA was pur-
chased from Upstate. Plasmid pBS-Wnt3-HA containing full-length
human Wnt3 and plasmid BA-Wnt10b containing full-length
mouse Wnt10b were from Addgene. Plasmid pcDNA3-Wnt3-HA
was constructed by ligating the EcoR1–Xba1 fragment containing
the full-length Wnt3 cDNA with HA tag from pBS-Wnt3-HA into
the EcoR1–Xba1 site of pcDNA3 vector. A b-galactosidase express-
ing vector and the luciferase and b-galactosidase assay systems
were purchased from Promega. Preparation of recombinant mouse
Mesd protein has been described before [5]. The monoclonal anti-
HA antibody was generated as previously described [13]. The
peroxidase-labeled anti-mouse antibody and ECL systemwere pur-
chased from Amersham Life Science.
2.2. Cell culture
HEK293 and PC-3 cells were purchased from American Type
Culture Collection. HEK293 and PC-3 cells were maintained inDulbecco’s modiﬁed Eagle’s medium and Roswell Park Memorial
Institute medium-1640, respectively. Both media were supple-
mented with 10% fetal bovine serum, 2 mM L-glutamine,
100 units/ml penicillin and 100 mg/ml streptomycin.
2.3. Luciferase reporter assay
Unlike our previous study (8), we used Super8XTOPFlash repor-
ter (kindly provided by Dr. Randall T. Moon, University of
Washington, Seattle) for the Wnt/b-catenin signaling reporter as-
say in the current study. Super8XTOPFlash reporter has a much
higher signal/noise ratio than TOPFlash reporter (The Wnt home-
page: http://www.stanford.edu/group/nusselab/cgi-bin/wnt/).
HEK293 and PC-3 cells were plated into 24-well plates. After over-
night culture, the cells were transiently transfected with various
Wnt plasmids, LRP5 or LRP6 plasmid along with Super8XTOPFlash
plasmid and b-galactosidase-expressing vector by FuGENE HD
(Roche). After 24 h incubation, cells were treated with Mesd. Cells
were then lysed 24 h later and both luciferase and b-galactosidase
activities were determined. The luciferase activity was normalized
to the b-galactosidase activity.
2.4. Western blotting
Cells in six-well plates were lysed in 0.5 ml of phosphate-buf-
fered saline (PBS) containing 1% Triton X-100, 1 mM PMSF and
1 protease inhibitor cocktail (lysis buffer) at 4 C for 10 min.
Equal quantities of protein were subjected to SDS–PAGE under
reducing conditions, and transferred to immobilon-P transfer
membrane. Membranes were blocked with 5% non-fat milk in
PBS containing 0.1% Tween 20 (blocking buffer) for 0.5 h at room
temperature, and incubated overnight at 4 C with anti-b-catenin
(1:5000, BD Biosciences), anti-Wnt1 (1:3000, RD Systems), anti-
Wnt3 (1:3000, Sigma–Aldrich), anti-Wnt10b (1:8000, Sigma
–Aldrich), anti-LRP5 (1:1000, MyBiosource), anti-LRP6 (1:500, San-
ta Cruz Biotechnology), or anti-actin (1:5000, Sigma–Aldrich) anti-
body diluted in the blocking buffer. After several washes with PBS
containing 0.1% Tween 20, membranes were incubated in the
blocking buffer with horseradish peroxide conjugated secondary
antibody for 60 min at room temperature. After washing, the
immunoreactive proteins were then detected using the ECL sys-
tem. Films showing immunoreactive bands were scanned by Kodak
Digital Science DC120 Zoom Digital Camera.
2.5. Cytosolic free b-catenin analysis with GST-E-cadherin binding
assay
The GST-E-cadherin binding assay was carried out exactly as de-
scribed [14]. Brieﬂy, cells were lysed in 0.5 ml of lysis buffer at 4 C
for 10 min, and extractswere clariﬁed by centrifugation at 18 000g
for 2 min. One hundred micrograms of total cell extracts
were incubated with Sepahrose beads bound to the GST-E
-cadherin. The GST-E-cadherin Sepahrose beads were prepared as
described [14]. After 1 h of incubation at 4 C, the Sepharose beads
were collected by centrifugation at 10 000g for 1 min, washed 2
times with lysis buffer containing 0.1% SDS and 0.5% bovine serum
albumin and 2 times with PBS buffer, and boiled in SDS sample buf-
fer containing b-mercaptoethanol. The supernatantswere subjected
to SDS–PAGE and Western blotting with the b-catenin antibody.
2.6. In vivo tumor suppression study
The antitumor efﬁcacy of Mesd was evaluated in a mouse model
using human PC-3 tumor fragments (from an in vivo established
line) that were implanted subcutaneously in 5–6 week old male
NCr-nu/nu athymic mice. The day of tumor implantation was
Fig. 2. Mesd blocks Wnt/b-catenin signaling reporter activities induced by LRP5 or LRP6 in combination with Wnt1, Wnt3 or Wnt10b in HEK293 cells. HEK293 cells in 24-
well plates were transiently transfected with the LRP6 (A and C) or LRP5 (B and D) in combination with Wnt1 (A and B), Wnt10b (C and D) or the corresponding control vector,
along with the Super8XTOPFlash construct and the b-galactosidase expressing vector in each well. After being incubated for 24 h, cells were treated with 1 lM Mesd. The
luciferase activity was then measured 24 h later with normalization to the activity of the b-galactosidase. Values are averages of three determinations with the standard
deviations indicated by error bars. ⁄⁄P < 0.01 compared to the control cells without Mesd treatment.
Fig. 3. Mesd blocks cytosolic free b-catenin accumulation induced by LRP5 or LRP6 in combination with Wnt10b in HEK293 cells. HEK293 cells in 6-well plates were
transiently transfected with LRP6 (A) or LRP5 (B) in combination with Wnt10b or the corresponding control vector. After being incubated for 24 h, cells were treated with
1.0 lM Mesd. Twenty-four hours later, the levels of cytosolic free b-catenin, LRP5, LRP6, and Wnt10b were analyzed with Western blotting using a speciﬁc antibody against
each protein. Samples were also probed with the anti actin antibody to verify equal loading. The pixels for each cytosolic free b-catenin band were measured, normalized and
plotted. Data are mean values of four independent experiments with the standard deviations indicated by error bars. ⁄P < 0.05, ⁄⁄P < 0.01 versus corresponding control value.
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ven every other day by intraperitoneal injection. There were 10
mice in each group. Tumor dimensions and body weights were
measured twice weekly. Tumor volume was calculated as x2y/2,where x = width, y = length, and x < y. This formula was also used
to calculate tumor weight, assuming unit density (1 mm3 = 1 mg).
All animal protocols were reviewed by the Southern Research IA-
CUC prior to experimentation.
Fig. 4. Mesd blocks Wnt1-induced Wnt/b-catenin signaling in PC-3 cells. (A) PC-3
cells in 24-well plates were transiently transfected with 0.1 lg Wnt1 plasmid or the
corresponding control vector, along with 0.05 lg Super8XTOPFlash construct and
0.05 lg b-galactosidase-expressing vector in each well. After being incubated for
24 h, cells were treated with Mesd at the indicated concentrations. The luciferase
activity was then measured 24 h later with normalization to the activity of the b-
galactosidase. Values are averages of three determinations with the standard
deviations indicated by error bars. ⁄⁄P < 0.01 compared to the control cells without
Mesd treatment. (B) PC-3 cells in 6-well plates were transiently transfected with
1.0 lg Wnt1 plasmid or the corresponding control vector. After being incubated for
24 h, cells were treated with Mesd at the indicated concentrations. Twenty-four
hours later, the levels of total b-catenin, free b-catenin, and Wnt1 were analyzed
with Western blotting using a speciﬁc anti-b-catenin or anti-Wnt1 antibody.
Samples were also probed with the anti-actin antibody to verify equal loading.
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The slides were prepared by the Pathology Core Facility at
Southern Research Institute using a standard protocol. Immunohis-
tochemistry for Ki67 (clone B56, BD Bioscience, 1:25 dilution) was
carried out, with antigen retrieval using BD Bioscience Retrievagen
solution, and detection via a BD Bioscience three-step staining
procedure according to manufacturer-recommended protocol.
2.8. Statistics
Statistical analyses were performed using Student’s unpaired
t-test for in vitro studies or one-way ANOVA analysis with Tukey
post test for in vivo tumor suppression study with a signiﬁcance
level of 60.05.
3. Results
3.1. Mesd suppresses Wnt/b-catenin signaling induced by Wnt1, Wnt3
and Wnt10b in HEK293 cells
Recent studies indicated that different Wnt proteins bind to dis-
tinct regions of LRP5 and LRP6 [10–12]. In our previous study, we
demonstrated that Mesd blocks Wnt3a-induced Wnt/b-catenin
signaling [8]. Like Wnt3a, Wnt3 binds only to a fragment contain-
ing LRP6 E3-E4 region, whereas Wnt 1 and Wnt10b bind exclu-
sively within the LRP6 E1-E2 region [10–12]. Initially, we
performed Wnt/b-catenin signaling reporter assay to test whetherMesd blocks Wnt/b-catenin signaling induced by different Wnt
proteins. As expected, Wnt1, Wnt3 or Wnt10b expression resulted
in a signiﬁcant increase of Super8XTOPFlash activity in HEK293
cells (Fig. 1A). Importantly, we also found that the Super8XTOP-
Flash activity induced by Wnt1, Wnt3 or Wnt10b was greatly
inhibited by Mesd treatment (Fig. 1A). It is also interesting to note
that the inhibitory effect of Mesd on the Wnt3-induced
Super8XTOPFlash activity was not as obvious as on the Wnt1 or
Wnt10b-induced Super8XTOPFlash activity, suggesting that Mesd
has different levels of inhibition towards different Wnt proteins.
To conﬁrm the inhibitory effects of Mesd on Wnt1, Wnt3 or
Wnt10b-induced Wnt/b-catenin signaling, we examined the level
of cytosolic free b-catenin after Mesd treatment. We found that
Wnt1, Wnt3 or Wnt10b expression resulted in an increase of cyto-
solic free b-catenin levels in HEK293 cells, and that the increased
cytosolic free b-catenin levels were signiﬁcantly reduced after
Mesd treatment (Fig. 1B). In addition, the increased total cellular
b-catenin levels in Wnt1 or Wnt10b-expresssing cells were also
decreased after Mesd treatment (Fig. 1B).
3.2. Mesd suppresses Wnt/b-catenin signaling induced by Wnt1, Wnt3
and Wnt10b in LRP5 or LRP6 expressing HEK293 cells
LRP5 and LRP6 are essential Wnt co-receptors. LRP5 or LRP6
expression resulted in a signiﬁcant increase of Super8XTOPFlash
activity in HEK293 cells. Wnt1, Wnt3 or Wnt10b co-expression en-
hanced the Super8XTOPFlash activity in LRP5- and LRP6-express-
ing HEK293 cells. Importantly, the increased Super8XTOPFlash
activity induced by LRP5, LRP6, Wnt1, Wnt3, Wnt10b, LRP5 plus
Wnt, or LRP6 plus Wnt was blocked by Mesd treatment (Fig. 2
and Supplementary Fig. 1). The expression of LRP5, LRP6, LRP5 plus
Wnt3 or Wnt10b, or LRP6 plus Wnt3 or Wnt10b also resulted in
signiﬁcant increases of cytosolic free b-catenin levels. As expected,
the increased levels of cytosolic free b-catenin were suppressed by
Mesd treatment (Fig. 3 and Supplementary Fig. 2). The levels of to-
tal cellular b-catenin were also reduced after Mesd treatment,
although the changes were not as obvious as the levels of cytosolic
free b-catenin (Fig. 3 and Supplementary Fig. 2).
3.3. Mesd suppresses Wnt/b-catenin signaling induced by Wnt1 in
prostate cancer PC-3 cells
Overexpression of Wnt1 was found in the majority of prostate
carcinoma specimens [15], suggesting that Wnt1 could play a
direct role in promoting prostate carcinoma development and pro-
gression. In our previous study, we demonstrated that Mesd treat-
ment inhibits Wnt/b-catenin signaling in prostate cancer PC-3 cells
[8]. To test whether Mesd is able to suppress Wnt1-induced Wnt/
b-catenin signaling in prostate cancer cells, we transiently trans-
fected PC-3 cells with Wnt1 and treated with Mesd. We found that
Wnt1 expression resulted in an increase of Super8XTOPFlash activ-
ity in PC-3 cells, and that the increased Super8XTOPFlash activity
was blocked by Mesd treatment (Fig. 4A). Accordingly, the in-
creases of cytosolic free b-catenin level by Wnt1 were also sup-
pressed by Mesd treatment (Fig. 4B).
3.4. Mesd inhibits tumor growth in prostate cancer PC-3 xenograft
model
In our previous study, we demonstrated that Mesd treatment
suppress PC-3 cell proliferation in vitro [8]. Therefore, Mesd was
further evaluated for in vivo antitumor efﬁcacy in a mouse xeno-
graft model using s.c. implanted human PC-3 tumor fragments.
As shown in Fig. 5A, Mesd was tolerated for the duration of treat-
ment. The body weight of the treatment group was comparable
with the control group on any given day. The ﬁnal body weight loss
3124 C. Lin et al. / FEBS Letters 585 (2011) 3120–3125was 12% in the treatment group, while it was 17% in the control
group. (The PC-3 model is cachexic.) On the other hand, Mesd
treatment signiﬁcantly attenuated PC-3 cell tumor growth in athy-
mic mice (Fig. 5B). The mean tumor weight in treated mice was re-
duced by 42% (P < 0.05) compared with the control group on day
21 (Fig. 5B). We also characterized tumors for expression of cell
proliferation marker Ki67, and found that Ki67 expression was sig-
niﬁcantly decreased in Mesd-treated tumors (Fig. 5C).
4. Discussion
LRP5 and LRP6 are subjected to modulation by several secreted
proteins which bind to the b-propeller/EGF repeat modules of
LRP5/6 [1,4,9–12]. Different Wnt proteins require different b-pro-
peller/EGF regions of LRP6 for Wnt/b-catenin signaling. Wnt 1
and Wnt10b speciﬁcally bind to the b-propeller/EGF region E1-E2
of LRP6 in vitro, whereas Wnt3 and Wnt3a bind only to a fragment
containing the b-propeller/EGF region E3-E4 [10–12]. Interestingly,
antibodies recognizing b-propeller/EGF region E1-E2 or E3-E4 of
LRP6 speciﬁcally inhibit Wnt/b signaling induced by the Wnt
proteins that bind these regions [11,12]. Mesd binds to both the se-
creted mature b-propeller/EGF modules E1-E2 and E3-E4 of LRP6
[16], although it is still unclear whether a single molecule of Mesd
is able to bind simultaneously to both E1-E2 and E3-E4 regions of
LRP6. In our previous study, we reported that Mesd blocked
Wnt3a-induced Wnt/b-catenin signaling in LRP5/6-expressing
cells [8]. In the present study, we further demonstrated that Mesd
was able to block Wnt1, Wnt3 and Wnt10b-induced Wnt/b-cate-
nin signaling in LRP5/6-expressing cells, indicating that Mesd is a
general Wnt inhibitor that blocks Wnt/b-catenin signaling induced
not only by LRP6 E1-E2-bindingWnts but also by LRP6 E3-E4-bind-
ing Wnts. By performing coimmunoprecipitation experiments, weFig. 5. In vivo antitumor efﬁcacy of Mesd with the human PC-3 prostate tumor xenogra
saline) or Mesd given every other day by intraperitoneal injection for 11 treatments (da
growth of mice treated with vehicle or Mesd at the dosage and schedule as described
standard errors indicated by error bars. ⁄P < 0.05 compared to the control mice without M
tumors with or without Mesd treatment. Bar: 20 lm.found that Mesd does not directly bind to b-catenin (data not
shown), supporting the notion that the inhibitory effect of Mesd
on Wnt/b-catenin signaling occurs on the cell surface.
While genetic mutations of certain intracellular components of
the Wnt/b-catenin pathway, such as APC and CTNNB1, are signiﬁ-
cant contributing factors for colorectal cancers, dysregulation of
cell surface Wnt/b-catenin signaling components could be an
important mechanism associated with aberrant activation of this
pathway in prostate cancer [17–19]. Overexpression of Wnt1 and
accumulation of cytoplasmic/nuclear b-catenin were found in the
majority of prostate carcinoma specimens, and were associated
with advanced, metastatic, hormone-refractory prostate carcinoma
[15]. ERG-mediated oncogenesis in prostate cancer was linked with
activation of Wnt/b-catenin signaling through Wnt receptor Fz-4
[20]. In addition, gene silencing mediated through aberrant
promoter methylation of upstream Wnt antagonist genes also re-
sulted in constitutive activation of Wnt/b-catenin signaling in
prostate cancer [21,22]. As a correlate, treatment of prostate cancer
LNCaP cells with Wnt3a signiﬁcantly enhanced cell growth [23],
whereas blocking Wnt/b-catenin signaling in prostate cancer cells
either by the non-steroidal anti-inﬂammatory drugs or small mol-
ecule Wnt/b-catenin signaling inhibitor PKF118–310 resulted in
inhibition of prostate cancer cell proliferation [24]. Furthermore,
the Wnt inhibitory factor 1 restoration in prostate cancer cells
was associated with reduced tumor growth, decreased capacity
of cell migration and invasion and a reversal of epithelial to mesen-
chymal transition [25]. In our recent study, we showed that recom-
binant Mesd protein suppressed Wnt/b-catenin signaling in
prostate cancer PC-3 cells, in which Wnt/b-catenin signaling is
highly activated, and inhibits PC-3 cell proliferation in vitro [8].
In the present study, we further demonstrated that recombinant
Mesd protein was able to inhibit tumor growth in PC-3 xenograftft mouse model. (A) Body weights of mice treated with vehicle (phosphate buffered
ys 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, and 21) at a dosage of 12.5 mg/kg/dose. (B) Tumor
in (A). Values are averages of tumor weights from 10 mice in each group with the
esd treatment. (C) Immunohistochemical staining with anti-Ki67 antibody of PC-3
C. Lin et al. / FEBS Letters 585 (2011) 3120–3125 3125model. Our results support the notion that the Wnt/b-catenin sig-
naling pathway is a promising therapeutic target in prostate cancer
treatment [6].
Both LRP5 and LRP6 are expressed in human cancer cell lines
and human malignant tissues [26]. LRP5 deﬁcient mammary
glands were remarkably resistant to Wnt1-induced tumor devel-
opment [27], whereas overexpression of LRP6 in the mouse mam-
mary gland is sufﬁcient to induce mammary hyperplasia [28].
Overexpression of a dominant-negative LRP5 mutant in osteosar-
coma Saos-2 cells and prostate cancer PC-3 cells down-regulated
Wnt/b-catenin signaling, and reduced cell invasion capacity and
cell motility in vitro [29], and tumor growth in a xenograft mouse
model [30]. In the present study, we demonstrated that recombi-
nant Mesd protein was able to suppress PC-3 tumor growth
in vivo. Consistent with our ﬁndings, it has been reported that
in vivo administration of Mesd also suppressed growth of
MMTV-Wnt1 tumors without causing undesirable side effects
[31]. Altogether, these ﬁnding suggest that LRP5 and LRP6 are po-
tential therapeutic targets for Wnt-dependent cancers.
In summary, we have demonstrated that recombinant Mesd
protein was a general inhibitor for different Wnts in Wnt/LRP sig-
naling activation, and was able to suppress the growth of PC3 pros-
tate cancer xenografts in nude mice. Our results also suggest that
Mesd is a useful research tool to study the function of Wnt/LRP sig-
naling on the cell surface in various pathophysiological conditions
such as bone metabolism, stem cells and cancer.
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